Lots of interesting abstracts and cases were submitted for TCTAP 2025. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-058
Efficacy of High Dose Atorvastatin in the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis
By Catherine Jillian Hardi, Jesslyn Natalie Hariyanto, Jessica Anastasia Setiawan, Sunanto Ng
Presenter
Catherine Jillian Hardi
Authors
Catherine Jillian Hardi1, Jesslyn Natalie Hariyanto1, Jessica Anastasia Setiawan1, Sunanto Ng2
Affiliation
Universitas Pelita Harapan, Indonesia1, Siloam Hospital Lippo Village, Indonesia2
View Study Report
TCTAP A-058
Pharmacotherapy (Coronary)
Efficacy of High Dose Atorvastatin in the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis
Catherine Jillian Hardi1, Jesslyn Natalie Hariyanto1, Jessica Anastasia Setiawan1, Sunanto Ng2
Universitas Pelita Harapan, Indonesia1, Siloam Hospital Lippo Village, Indonesia2
Background
Statin pretreatment is a promising strategy in the prevention of the development of contrast-induced nephropathy (CIN). Statins are thought to exert renoprotective effects in CIN via blocking the absorption of contrast media into renal tubular cells. The efficacy of high dose atorvastatin in CIN prevention has shown conflicting results. We conducted a systematic review and meta-analysis to evaluate the efficacy of atorvastatin on CIN prevention after angiography and PCI.
Methods
We searched through PubMed, EMBASE and Cochrane databases for studies on preprocedural high dose (80 mg) atorvastatin treatment for prevention of CIN from inception up to November 2024. The primary outcome was the incidence of CIN, defined as postprocedural increase in serum creatinine ≥25% or ≥0.5 mg/dl from baseline. We computed pooled risk ratios (RR) with 95% confidence intervals (CI). Review Manager was used for analysis.
Results
A total of 18 RCTs included 4133 patients, 66.2% are male averaging 55 years old, 2076 patients who were given atorvastatin 80 mg as pretreatment and 2057 patients as control. Normal saline was administered intravenously prior to procedure as per standard protocol. Patients who received atorvastatin 80 mg had lower incidence of CIN (8.4%) compared to the control group (11.2%). Overall, atorvastatin 80 mg pretreatment significantly reduced the prevalence of CIN (RR 0.73; 95% CI 0.61 - 0.89; p = 0.001). There was a significant protective effect of preprocedural atorvastatin on the incidence of CIN when compared to placebo (RR 0.55; 95% CI 0.33 - 0.63; p < 0.00001) and atorvastatin routine dose (RR 0.59; 95% CI 0.39 - 0.88; p = 0.01). Atorvastatin was not significantly more protective in comparison to other high dose statins (RR 1.30; 95% CI 0.97 - 1.74; p = 0.08). Atorvastatin’s protective effect was also significant in patients with impaired renal function (RR 0.48; 95% CI 0.27 - 0.84; p = 0.01).
Conclusion
Pretreatment with a high dose of atorvastatin is linked to a significant reduction of the prevalence of CIN and should be strongly considered for all patients scheduled for diagnostic or interventional procedures involving contrast media.